# Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

> **NCT02781584** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 220 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Nonalcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** SEL
- **DRUG:** FIR
- **DRUG:** CILO
- **DRUG:** FENO
- **DRUG:** VAS

## Key facts

- **NCT ID:** NCT02781584
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-13
- **Primary completion:** 2020-12-17
- **Final completion:** 2020-12-17
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02781584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02781584, "Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02781584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*